Article
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
Haematologica - 1 May 2011
Du Juan, Huo Jun, Shi Jun, Yuan Zhengang, Zhang Chunyang, Fu Weijun, Jiang Hua, Yi Qing, Hou Jian
Abstract excerpt
BACKGROUND: The nuclear factor-κB pathway is an important signaling pathway activated in multiple myeloma cells. Bortezomib inhibits nuclear factor-κB activation and is an important antimyeloma agent. Nevertheless, patients treated with this drug eventually relapse. We hypothesized that the nuclear factor-κB pathway may be associated with multiple myeloma and patients' responses to bortezomib. DESIGN AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.